Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis

Dworkin, Ronald J.; Modin, Gunnard; Kunz, Stefan; Rich, Robert R.; Zak, O.; Sande, Merle A.

doi:10.1128/aac.34.6.1014

Cited by 74 publications

(46 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rifampicin is a potent antibiotic that is especially effective against Staphylococcus, which sometimes show resistance to beta-lactam antibiotics (Henry et al, 1987;Dworkin et al, 1990;O'Reilly et al, 1992;Littlewood-Evans et al, 1997;Rissing, 1997;Costerton et al, 1999). Furthermore, rifampicin has been shown to be an effective agent for treating bacteria in biofilms (Widmer et al, 1992), which Costerton et al (1999) reported to be important in the pathogenesis of bone and joint infection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of rifampicin on osteogenic differentiation and proliferation of human mesenchymal stem cells in the bone marrow

et al. 2014

View full text Add to dashboard Cite

ABSTRACT. This study was designed to investigate the effect of different concentrations of rifampicin on osteogenic differentiation and proliferation of mesenchymal stem cells (MSCs) in human bone marrow. Rifampicin treatment at 0, 4, 8, 16, 32, 64, and 128 mg/mL was applied throughout the whole process, from stromal cells purified from human bone marrow to differentiated bone cells. The effect of rifampicin on MSC proliferation was determined using the MTT assay. The effect of rifampicin on the expressions of type I collagen (COL1A1), osteopontin/ bone Gla protein (OPN/BGP), and alkaline phosphatase (ALP) in human osteoblast cells were determined by real-time polymerase chain reaction, and the expressions of COL1A1, OPN/BGP, and the runt-related transcription factor (RUNX2) were determined by Western blot. Results showed that the proliferation of MSCs was significantly inhibited when the rifampicin concentration exceeded 32 mg/mL. In addition, increased rifampicin concentrations inhibited the formation of calcium nodules, OPN/BGP, and COL1A1 in osteoblasts after 28 days of induction. The RNA expressions of OPN/BGP, COL1A1, and ALP were significantly downregulated compared to those of the control group in osteoblasts 6399 ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 13 (3): 6398-6410 (2014) Rifampicin and MSC proliferation and differentiation after induction. The protein expressions of RUNX2, COL1A1, and OPN/BGP were also significantly downregulated compared to those of the control group after induction. In conclusion, rifampicin at exorbitant concentration exerts adverse effects on the proliferation of MSCs in human bone marrow and the differentiation of osteoblasts.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The efficiency of the combination therapy of rifampicin and ciprofloxacin in controlling orthopedic infections has been demonstrated in clinical and experimental studies (Hendry et al, 1987;Dworkin et al, 1990).…”

Section: Introductionmentioning

confidence: 99%

Effects of rifampicin on osteogenic differentiation and proliferation of human mesenchymal stem cells in the bone marrow

et al. 2014

View full text Add to dashboard Cite

show abstract

“…They both have excellent oral bioavailability and safety, allowing them to be used for prolonged courses of therapy. The quinolone-rifampin combinations that have been studied include ciprofloxacin, perfloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin (18,73,74,106,117,137,279).…”

Section: Staphylococcimentioning

confidence: 99%

Rifampin Combination Therapy for Nonmycobacterial Infections

2010

View full text Add to dashboard Cite

SUMMARY The increasing emergence of antimicrobial-resistant organisms, especially methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy. The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clinical studies. Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations. A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed. The clinical data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-negative staphylococci. Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clinically or experimentally. Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections. Lastly, an assessment of the risk-benefits is needed before the addition of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities.

show abstract

“…Although the bactericidal agent rifampin has excellent antistaphylococcal activity, the emergence of rifampin resistance when used as a single agent has limited its use in this manner (19)(20)(21). This development of rifampin resistance in infections that are difficult to treat (endocarditis and osteomyelitis) has been documented in many papers and supports the requirement that rifampin should not be administered as a single agent (2,4,8,9,13). Studies of the combination of rifampin and other antibacterials have reported mixed results, with several studies reporting antagonism or indifference (2,5,17,18).…”

mentioning

confidence: 99%

Efficacy of Linezolid plus Rifampin in an Experimental Model of Methicillin-Susceptible Staphylococcus aureus Endocarditis

Dailey¹,

Pagano²,

Buchanan³

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The efficacy of linezolid, alone or in combination with rifampin, against methicillin-susceptible Staphylococcus aureus in rabbits with experimental endocarditis was investigated. Linezolid (50 or 75 mg/kg of body weight), rifampin, and linezolid (25, 50, or 75 mg/kg) plus rifampin produced statistically significant reductions in bacterial counts compared with those in untreated controls. Plasma or valvular vegetation levels of linezolid in the groups treated with the linezolid-rifampin combination were similar to those in the respective linezolid-only treatment groups. At therapeutic levels of linezolid, rifampin resistance was not observed. The results from this experimental model of endocarditis suggest that while rifampin did not provide synergy to the linezolid dosing, it did not antagonize the efficacy of linezolid.

show abstract

Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis

Cited by 74 publications

References 15 publications

Effects of rifampicin on osteogenic differentiation and proliferation of human mesenchymal stem cells in the bone marrow

Effects of rifampicin on osteogenic differentiation and proliferation of human mesenchymal stem cells in the bone marrow

Rifampin Combination Therapy for Nonmycobacterial Infections

Efficacy of Linezolid plus Rifampin in an Experimental Model of Methicillin-Susceptible Staphylococcus aureus Endocarditis

Contact Info

Product

Resources

About